The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Dec 2015
Randomized Controlled Trial Multicenter StudyPreseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure. ⋯ Adding omalizumab before return to school to ongoing guidelines-based care among inner-city youth reduces fall asthma exacerbations, particularly among those with a recent exacerbation.
-
J. Allergy Clin. Immunol. · Dec 2015
ReviewPatient-reported outcome measures for adult chronic rhinosinusitis: A systematic review and quality assessment.
With a focus on patient-centered care, there is increasing policy interest in patient-reported outcome measures (PROMs) to inform improvements in health care delivery. Given the importance of understanding patient-reported outcomes during the management of chronic rhinosinusitis (CRS), PROMs will play an essential role in informing and tailoring the right intervention to the right patient. ⋯ Based on quality assessment, the 22-item Sinonasal Outcome Test, the Questionnaire of Olfactory Disorders, and the Sinusitis Control Test provided the highest quality CRS-specific PROMs, whereas the EQ-5D provided the highest quality generic quality-of-life instrument. Future CRS PROMs will need to incorporate clinical domains that assess common comorbid diseases along with patient values and preferences to improve clinical decision making.
-
J. Allergy Clin. Immunol. · Dec 2015
IL-2 is a critical regulator of group 2 innate lymphoid cell function during pulmonary inflammation.
Group 2 innate lymphoid cells (ILC2) have been implicated in the pathogenesis of allergic lung diseases. However, the upstream signals that regulate ILC2 function during pulmonary inflammation remain poorly understood. ILC2s have been shown to respond to exogenous IL-2, but the importance of endogenous IL-2 in ILC2 function in vivo remains unclear. ⋯ Innate cell-derived IL-2 is a critical cofactor in regulating ILC2 function in pulmonary type 2 pathology.